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Immunological aspects of neoplastic diseases
V. Radhakrishna, M.D.*

AF
GROUND

The immunological approach to neoplastic disease is gaining favor because malignant tumors are associated with Immunodeflclent states. Mesenchymal tumors have
been seen in renal allograft recipients. The
discovery of carcinoembryonic antigen, alfafetoprotein and other protein antigens associated with malignant diseases are other
factors. Spontaneous regression of malignant neoplasm has been attributed to
an effective immunologic
process In the
host. Identification of tumor specific antigens may explain these spontaneous tumor
regressions.

1950 the concept developed
that cancer might be due to the deletion of
some components necessary for maintaining normal relationship between cells in a
tissue. The term "surveillance" was first
coined by Burnet' based on the occurrence
of spontaneous tumors in renal transplantation patients who were receiving long-term
immunosuppressive therapy. He hypothesized that a clone of malignant cells arises
at regular intervals in all individuals, but
cells are rejected as allografts unless there is
some unspecified defect in i m m u n e response. This certainly is a stimulating idea
but it is still not clear how we are protected
from o n c o g e n i c events by the i m m u n e
mechanism.

It may not be too optimistic to expect
tumor vaccine of some sort within the next
few years.
B.C.G. and other nonspecific
Immunostlmulants are under Investigation for
treatment of malignant tumors. Transfer factor has been extensively used in the last 20
years and seems to be useful in certain types
of tumors. Immune RNA may be a reasonable approach
to adoptive
transfer of
immunity.

T u m o r antigens

O f a l l the parts that theoretically may be
transformed in malignancy, the cell surface
may be the most important The discovery of
tumor specific andgens (TSA) on the cell
surface may permit early diagnosis.^ Although TSA are probably not only confined
to the surface, they are most readily detected
on intactcells. Moreover,TSAonthe surface
are sensitive to the immune response which
may result in tumor destruction.

* Fellow, Division of Oncology.
Address reprint requests to author at Midwest
Oncology Centre, 1521 Gull Road, Stryker Building, Kalamazoo, Ml 49001
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(a) Tumor specific antigens. Immunological methods which are specific, sensitive
and relatively inexpensive may soon be the
best means to d iagnose cancers that produce
distinctive antigens. Unfortunately, all cancers are not alike in this respect, so only
some of them may be detected by immunological means. In chemically induced tumors, the new tumor antigens are different
for each tumor. Even two tumors induced in
the same animal by the same carcinogen
appear to be antigenically different from
each other (Figure 1).

viruses. Two groups of viruses have been
consistently associated with naturally occurring cancer—oncornaviruses containing
single stranded RNA, and herpes virus with
double stranded DNA.
The most important characteristic of oncornaviruses is that they contain DNA polymerase (Reverse Transcriptase). This enzyme
reverses the usual direction of information
( D N A ^ RNA) so that DNA is produced for
RNA template. This DNA intermediate is
then integrated with the host genome, causing neoplastic transformation by some unknown mechanism.
In man, Epstein-Barr virus (herpes group)
has been associated with Burkitt's lymphoma, n a s o p h a r y n g e a l c a r c i n o m a and
Hodgkin's disease. One of the most extensively studied virus-associated cancers is
carcinoma of cervix, where there is a constant elevation of herpes simplex Type II
virus antibodies in patients.

tumor specific antigens

There is good circumstantial evidence that
RNA and D N A viruses cause c a n c e r . '
Whether or not cancer develops following
exposure to these viruses probably depends
on the immunologic response ofthe infected
animal. Spontaneously occurring tumors
were long considered to lack TSA. The exact
nature of TSA is not known but it may be part
of virus particles or component of tumor

tumor specific antigens

Figure 1
Tumor antigens induced by chemical carcinogens. When cells of identical genetic background are transformed with the same chemical
carcinogen, each new tumor has its own antigenic specificity which is not shared with other
tumors. (Immunology monograph by Upjohn Co.
1975)

cells.'
(b) Carcinoembryonic antigen (CEA). In
1965 Gold demonstrated the presence of a
glycoprotein antigen in patients with cancer
of the colon." Subsequently this antigen was
shown to be present in up to 97% of such
patients with metastasis.^ Further studies revealed that the levels of CEA vary with the
stage ofthe disease. In three series of studies
the CEA level varied from a low of 19% to
40% in patients with localized disease to a
high of 100% in patients with disseminated
disease, especially of the l i v e r . B u t the
greatest limitation of screening by CEA is its
nonspecif icity for cancer ofthe colon. Many
other types of cancers have elevated levels

On the other hand, animal tumors induced by viruses develop a new antigen that is
common to all the tumors induced by the
same virus, even though the tissue origins of
tumors are different (Figure 2). Both DNA
and RNA viruses can induce these antigen
specific tumors. Among DNA viruses that
can code for new antigens are herpes viruses, adenoviruses, plyoma and papilloma
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tumor specific
antigens
T-antlgens

complete
virus
particles

Figure 2
Three new antigens in a virus transformed cell. Virus capsid antigen and new virus particles may be found
in the malignant transformed cell recently infected and destined to undergo lysis. (Immunology
monograph by Uplohn Co. 1975)

of CEA. For example, CEA is elevated in as
many as 90% of patients with pancreatic
carcinoma^ (Table 1). Nor is elevated CEA
limited to malignant diseases. Many benign
disorders also have higher levels of CEA
(Table II) especially liver disease, alcoholic
pancreatitis and benign obstructive jaundice.' Most patients with inactive ulcerative
colitis have normal levels of CEA. Elevated
levels tend to correlate with exacerbation of
activity.'' Screening for CEA levels is most
useful in postoperative follow-up of patients
with colonic carcinoma. Many investigators
have confirmed that elevated CEA levels fell
to normal after resection of t u m o r .
Postoperative serial CEA determinations
may identify metastases before clinical evidence of spread of the disease.

normal levels of CEA do not preclude primary, metastatic or recurrent disease.^-'
(c) Alphafetoprotein (AFP). The association of AFP with primary liver cancer was
observed more than ten years ago." Though
originally thought to be specific for primary
hepatoma, AFP has been found to be elevated in several other conditions, including
some normal individuals' (Table 111). In primary hepatoma up to 70% of patients have
elevated AFP; 8 0 % of patients w i t h
teratocarcinoma and a small percentage of
patients with pancreatic, gastric, colonic
carcinoma also have elevated AFP levels.''''°

(d) Other Tumor Antigens
i) A l f a i - H Feto Protein is i m m u n o logically identical to ferritin and is present in
the liver and serum of the human fetus.'"
Though initially detected in about 60% of

Generally speaking, higher levels of CEA
are associated w i t h poorer prognosis.
However, several investigators confirm that
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patients with primary hepatoma, 50% of
patients w i t h various malignancies and
20-30% of certain benign disorders have
elevated alfa2 — H fetoprotein levels. In children hepatic Alfaa — HFP appears more spec i f i c (80% p o s i t i v i t y ) despite 10% false
positive results.'"

CEA Positivity in Cancer Table 1
Incidence of Positive Assays
Cancer
Percentage

Mo, cl CaM^s

Colon & Rectum

73

316

Pancreas

92

52

Uver

67

18

Breast

52

159

Cervix

42

45

Endometrium

27

11

Ovary

35

20

Testis

57

29

Prostate

40

93

Kidney

35

26

Bladder

33

106

Neuroblastoma

IX

6

Leukemia

22

27

Lymphoma

25

14

Bronctius

72

90

ii) Beta -S-fetroprotein and Gamma -Sfetoproteins are found in a wide variety of
malignant and nonmalignant conditions.
Specific data regarding these antigens is
lacking at this time.
iii) fetal sulfoglycoprotein antigen (ESA).
In initial studies 75 of 78 patients with gastric
carcinoma had elevated levels of ESA in their
gastric j u i c e . " But there was no fall in ESA
levels even after complete removal. FSA is
elevated in 10-15% of benign gastric ulcers.

Compilation of reported observations made with Gold, Hansen
or Todd assays from reports by Zamcheck. Lo Gerlo, Reynoso,
and Laurence, frtodified from Laurence and Neville.

CEA Positivity in Benign Disorders Table II
Incidence of Positive Assays
Disease
Percentage

No of Cases

Alcoholic cirrhosis, severe

45

88

Alcoholic pancreatitis

43

42

Pulmonary tuberculosis

38

21

Chronic bronchitis and emphysema

25

63

Inflammatory bowel disease

21

95

Diverticulitis and peptic ulcer

21

33

Colorectal polyps

9

67

Prostatic - hypertrophy

7

30

Breast - fibroadenosis

7

70

Gastric atrophy

5

19

Norman Zamchek M. D. and Gabor Pusztaszeri M. D.; CEA, AFP
and other potential tumor makers: CA-Cancer Journal for Clinicians,
vol. 25, Na 4 July/August 1975.
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iv) C a r c i n o p l a c e n t a l a l k a l i n e phosphatase is a nonspecific tumor marker and is
found in highest frequency in ovarian (45%),
testicular (40%) and pancreatic (30%)
cancers.'^

be indirectly observed by comparing the
i n c i d e n c e of neoplasia in i m m u n o s u p pressed and normal populations.

There is sufficient evidence that impairment of immunological capacity increases
the susceptibility to cancer and accelerates
its growth'" (Table IV). The use of immunosuppressive agents ( p a r t i c u l a r l y a n t i lymphocytic serum) to prevent rejection of a
grafted organ in man has provided further
support for the existence of immunological
surveillance that rids the body of incipient
neoplastic cells. The incidence of neoplasia
in patients with renal allograft transplant has
been 20 to 80 limes higher than in general
population.'" Most of these tumors are lymp h o r e t i c u l a r , e p i t h e l i a l or anaplastic in
nature.

v) Oncofetal antigens (OFA). In preliminary studies 29 of 30 patients with carcinoma
ofthe pancreas had high levels of oncofetal
antigens. Further work is needed to confirm
the importance of this antigen.'^

Evidence for a successful
immunological surveillance
That immunological factors influence the
natural course of certain tumors in man may

Table III
Serum Alpha-Fetroprotein in Patients with Cancer
No. of
samples
assayed

Diagnosis

Percent
over
40 ng./ml.

Hepatocellular carcinoma

180

72

Testicular teratxarcinoma

101

75

Pancreatic carcinoma

44

23

Gastric carcinoma

91

18

193
150

5
7

55

0

Nonhepatic benign lesions

300

0.3

Normal controls over 1 year of age

210

0

Colonic carcinoma
Bronchogenic carcinoma
Breast carcinoma

From: Waldmann, LA., and Mcintire, K.R.: The use of radio-immunoassay
for alpha-fetoprotein in the diagnosis of malignancy. Cancer 34: 1510-1515,
1974.
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Table IV
The Incidence of Primary Cancer in Immunologically
Deficient and Renal Transplant Patients
Disease
Sex-linked agammaglobulinemia*
(Brutons)

Percent Incidence
of Cancer
5
(10,000 X normal)

Severe combined immunodeficiency

Tumor Type
Acute lymphatic
leukemia

5

Lymphoreticular

Wiskott-Aldrich

10

Lymphoreticular

Common variable immunodeficiency

10

Lymphoreticular &
carcinomas

Isolated IgA

-

Adenocarcinoma of
stomach (one case)

Ataxia telangiectasia

10

Lymphoreticular, sarcoma,
carcinoma

Renal transplant patients

1.26(190/15,000)
(25 X normal)

Epithelial (62 percent)
Mesenchymal (38 percent)

•From Richard A. Gatti and Robert A. Good
••From Olga Jonasson and Israel Penn and Thomas t Starzl

Burnet' has studied denovo malignancies
in 42 renal homograft recipients and came
out with certain interesting points; viz:

g) Antilymphocytic globulin was given in
10 of 42 patients.
An unusual feature of lymphomas in this
series was the frequency with which the
brain was involved. Of 22 patients with
lymphomas, the brain was involved in 11 and
was the only organ involved in eight patients. There is enough evidence at least in
animals that acceleration of metastasis is
more frequent with azothiaprim and prednisone therapy.'" This may be true in
humans.

a) Patients tended to be of younger age
(8-54 years) with a mean of 33 years.
b) A l l had immunosuppression
azothiaprim and prednisone.

with

c) 21 of 42 cases (50% ) had mesenchymal
tumors (most c o m m o n l y r e t i c u l u m cell
sarcoma).
d) Highly malignant tumor tends to appear
much earlier after transplantation than the
relatively low grade malignancies of skin,
lips, etc.
e) Average time of appearance of tumors
after transplantation was 25 months.

Spontaneous cure of cancer

f) Thymus was not removed from any
patient.

Spontaneous cure of cancer has been a
puzzling curiosity for many years. It suggests
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yet another evidence for the existence of
immunological surveillance.

Mechanisms of immunological failure
Precancerous lesions in man can antedate
the emergence of frank malignancy by years,
ie:

Everson and Cole studied 176 cases of
cancer showing spontaneous regression.
More than half fell into one of the four
categories: a) malignant melanoma, b) neuroblastoma, c) carcinoma of kidney, or d)
choriocarcinoma. Lymphomas, leukemias
and soft tissue sarcomas are other examples
of o c c a s i o n a l regression. Though spontaneous regression does not unequivocally
prove the presence of tumor specific antigen, it is p r o b a b l y the most logical
explanation.

i)

Intestinal polyps preceding colonic
carcinoma.

ii) Solarkeratosisand leukoplakis preceding invasive squamous carcinoma.
iii) Dysplastic squamous epithelium of
cervix and bronchus converting into
carcinoma cervix and bronchus.
iv) Hydatiform moleconvertingtochoriocarcinoma.

More direct evidence for spontaneous
regression comes from histological findings.
In breast cancer, a positive correlation exists
between favorable prognosis and lymphoid
i n f i l t r a t i o n around the t u m o r w h e r e the
tumor is advancing and infiltrating. This
lymphoid and plasma cellular reaction suggests specific immunological reaction to
some component of tumor growth. Similarly,
highest survival rates w i t h gastric carcinomas are associated with lymphoid infiltration in the t u m o r itself and sinus
histiocytosis around regional lymphnodes
whether or not lymphnode metastasis is
present. It is interesting that these considerations have a higher correlation with survival
than adequate surgical removal of tumor.

Immunological surveillance in all these
conditions does notalways prevent development of tumor. So, what factors are responsible for escape of this i m m u n o l o g i c a l
surveillance? Postulations are various.'-'"
i)

Cancer could be a consequence of an
inherited selective defect in immunological surveillance. Leukemia induced by gross virus is seen in 100% of
susceptible mice, only 1 % of resistant
strains after exposure to 87 days in
both groups. However, leukemia developed in 25% of resistant strains
after 304 days when the immunological surveillance was broken down.'^

ii) Since neoplasm generally grows from
small f o c i of cells, these may not
provide sufficient antigenic stimulus at
an early stage of tumor growth to el icit
an immunological reaction. Therefore,
they sneak through the immunological
defense of the host. When the host is
sensitized, it may be too late to attack
an already established tumor.

The remarkably high cure obtained with
chemotherapy in Burkitt's lymphoma and
choriocarcinoma are attributed to concomitant immunity against strong foreign cell
surface antigens. The Epstein-Barr virus related antigen in Burkitt's lymphoma may be
responsible for the occasional spontaneous
regression seen. Where Burkitt's lymphoma
is resistant to chemotherapy, the patients
seem to accumulate an IGG layer on the
plasma membrane. This globulin apparently
renders the cells more immuno-resistant.
The 70% cure rate seen in choriocarcinoma,
particularly with methotrexate, appears to
come from an effective immune response in
these patients.

iii) Failure of immunological surveillance
may be due to tumor specific antigen
i n d u c i n g a state of i m m u n o l o g i c
tolerance.
iv) TSA may be coated by substances such
as sialomucin and, therefore, not recognized unlessthecoatingis removed.
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Immunotherapy

dren receiving B.C.G. vaccine compared to
control groups."

As the latest modality of approach for
treatment of neoplastic diseases, immunization may be prophylactic against a tumor the
patient is yet to encounter or therapeutic
against one that is already growing.

(2) Therapeutic approach of malignancy
may be:
a) Nonspecific immunotherapy,
b) Specific immunotherapy, or
c) Adoptive transfer of immunity.

(1) Prophylactic immunization. The ultimate goal of immunotherapy is prophylactic. Experimental models have demonstrated
the possibility of such immunization at two
levels—the causative agent and the tumor
specific antigen of neoplastic cell.'' The
most important target of this futuristic approach to therapy is the oncogenic viruses
isolated from human tumor. But two basic
problems face a p r o p h y l a c t i c vaccine
against tumors:

(A) Nonspecific immunotherapy is an attempt to stimulate the immune system with
adjuvants that have no antigenic relationship to the tumor. Several microbiological
agents are shown to be capable of general
stimulation of the lymphorecticular system.
In current clinical trials the most commonly
used materials are:'*-"
1. B a c i l l u s o f C a l m e t t e - G u e r i n
(B.C.G.)
2. M e t h a n o l e x t r a c t i o n residue of
B.C.G.
3. Corynebacterium parvum
4. Levamasole
5. Polynucleotides and polysaccharides

a) Each histologically different neoplasm
appears to have a different TSA. So, a new
vaccine would be necessary for each neoplasm arising from every organ site, eg,
colon, breast, lung, etc.
b) It is unlikely that all human tumors are
caused by the same virus. So, a separate
vaccine would be needed for each type of
virally-induced neoplasm.

In experimental models these agents have
inhibited the development of spontaneous
tumors, the induction of tumors by chemicals and viruses and the growth of transplantable tumors."^'" Nonspecific immunotherapy seems to promote both cell-mediated and humoral immunity and may be
effective in partially reversing the immunosuppression due to t u m o r and c h e m otherapy. B.C.G. and c o r y n e b a c t e r i u m
parvum are receiving the most extensive
clinical trials at the present t i m e . " . B.C.G.
trials are directed against m a l i g n a n t
melanoma, acute leukemia and soft tissue
sarcomas. In melanoma B.C.G. has produced up to 90% regression^" rate when
injected intralesionally. The response to
B.C.G. in melanoma occurs primarily in
those w i t h disease l i m i t e d to skin, sub-

In contrast, tumor vaccines based on nonspecific immunization might be feasible
m u c h sooner. Studies have shown that
Bacille Calmette-Guerin (B.C.G.) significantly decreased the development of many
spontaneous tumors in several strains of
m i c e . " Therefore, nonspecific stimulation
of immune response would have a greater
advantage over specific vaccine, since, theoretically, it could be effective against all
types of human neoplasia. Preliminary evidence suggesting the validity of such a statement comes from the work of Rosenthal and
associates w h o reported a s i g n i f i c a n t l y
lower incidence of acute leukemia in chil-
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cutaneous tissue and regional lymphnodes.
Patients with metastasis to parenchymal
organs such as lung, liver, and brain generally have little response to B.C.G.^"'^'

cells in the immediate vicinity of the tumor,
as well as normal cells, may be damaged or
destroyed. In addition, macrophages activated into a state of increased phagocytic
and metabol ic function seem to be able to
kill tumor cells.

Effects of B.C.G. in acute leukemia have
mixed results. Mathe^' conducted a controlled clinical test in 30 patients with acute
lymphatic leukemia who are in complete
remission f o l l o w i n g intensive c h e m otherapy. Ten of these patients who received
no further therapy relapsed within 130 days;
the other 20 patients receive irradiated leukemia cells, B.C.G. or both. There was a
significant prolongation of survival in the
latter group. But, studies carried out by
Childrens' Cancer Study Group A showed
that the group maintained with drugs had
relatively longer durations of remission than
either the control group or B.C.G.-treated
group. Results of further studies are awaited.
Initial trials of B.C.G. in acute myelogenous
leukemia are encouraging."

(B) Spec;f/c immunotherapy employs substances that are antigenically related to or
products of the tumor, such as killed tumor
cells from the same patient or from another
patient with antigenically similar tumor.
The approach most widely studied is to
alter the tumor cells with neuraminidase.
This enzyme removes the coating of sialic
acid that coats many of the tumor cells,
rendering the tumor more immunogenic.
Active specific immunotherapy may also
include the use of soluble tumor antigen
extracts prepared from tumor obtained at
surgery or at autopsy. Another approach is to
stimulate the patient's lymphocytes with his
own tumor cells (or antigen) by cultivating
them together in vitro. The lymphocytes
immunized in vitro can then be reinfused
into the patient, where they may have an
increased capacity to interact with tumors.

Besides intralesional injection, B.C.G. has
also been given by aerosol inhalation postoperatively to patients with lung cancer. In
addition B.C.G. has been introduced into the
pleural space subsequent to lung resection
in orderto reproduce the beneficial effects of
postoperative empyema. But it is too early to
evaluate the c l i n i c a l value of these approaches. Systemic administration of B.C.G.
has also been studied" as many cancers are
already disseminated by the time of diagnosis. In patients w i t h leukemia and
melanoma, B.C.G. has also been used either
by scarification or the multiple puncture
method."

(C) The adoptive transfer of immunity
involves transfer of specific immunity from
one individual to another. Two sources of
material, transfer factor and immune RNA,
appear to be capable of transferring immunological information. Both transfer factor
and immune RNA can be used to stimulate
lymphoid cells in vitro or they may be
injected directly into the recipient.
Transfer factor is a cell-free leukocyte
extract capable of transferring delayed hypersensitivity." It resists digestion by endogenous nucleases, lysosomal hydrolase,
deoxyribonuclease and ribonuclease. It is
dialysable. Transfer factor is neither antigenic nor an immunoglobulin fragment and
has a molecular weight of less than 10,000.

M e c h a n i s m of a c t i o n of B.C.G. W h y
should the injection of B.C.G. cause a tumor
to regress? The answer is not entirely clear,
but it is known that B.C.G. induces a local
sustained granulomatous inflammatory res p o n s e . " ' " As part of this response, various
cytotoxic substances are released and all
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Transfer factor has been used in a wide
variety of disorders" both malignant and
non-malignant, commonly where there is an
immunodeficient state. The various disorders in which transfer factor is useful are
shown in Table V.

tions would not be expected to
occur.
ii) There is no danger of inducing a
graft versus host reaction in the
immunosuppressed host.
The potential sources of immune
RNA are:
i)

TABLE V
CONDITIONS IN WHICH TRANSFER FACTOR
IS USED

From lymphocytes of patients who
have been cured of tumor or who
have undergone spontaneous
regression.

ii) From animals that have been specif i c a l l y i m m u n i z e d w i t h human
tumor.

Wiskott-Aldrich Syndrome
Mucocutaneous Candidiasis
Combined Immunodeficiency
Disease

Immune RNA has been used in renal cell
carcinoma with some success. Pilch et al
reviewed results of xenogenic RNA immunotherapy in 17 patients with various malignancies." One patient showed improvement and had stabilization of disease. The
studies with immune R N A " are still in early
stages and further trials are needed to assess
the value of this form of immunotherapy.
There have been no toxic reactions reported
with immune RNA. The major hazard is
thought to be potential sensitization to sheep
protein and subsequent prophylaxis. Some
patients may have slight discoloration of the
skin."-"

Coccidioidomycosis
Verruca Vulgaris
Dysgammaglobulinemia
Behcet's Disease
Aphthous Stomatitis
Linear Morphea
Familial Keratoacanthoma
Partial Di George
Ataxia Telangiectasia
Malignant Melanoma
Osteogenic Sarcoma
Hypernephroma
(Modified From: 'Therapeutic Uses of
Transfer Factor" by
H. H. Eudenberg et al Hospital Practice
January 1974
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Immune R N A ' s " ' " exact mechanism in
transfer of immunity is unknown. The theoretical advantages in support of adoptive
immunotherapy with immune RNA are:
i)

If it is not of itself antigenic even
after repeated injections, secondary syndromes or immune elimina-
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